Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Anna, Patrikidou"'
Autor:
Guillaume Grisay, Fabio Turco, Saskia Litiere, Béatrice Fournier, Anna Patrikidou, Enrique Gallardo, Ray McDermott, Ahu Alanya, Silke Gillessen, Bertrand Tombal
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation Therapy (ADT), significantly improving survival rates. However, prolonged use of these therapies
Externí odkaz:
https://doaj.org/article/81835467e73e4364af4a30938a8d05b9
Autor:
Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Valenca Bueno, Livia Maria Q. S. Andrade, Anna Patrikidou, Ricardo Pereira Mestre, Mikol Modesti, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini, the SPARTACUSS Investigators
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-7 (2023)
Abstract Background Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor signaling inhibitors abiraterone acetate plus prednisone (AA) and enzalutamid
Externí odkaz:
https://doaj.org/article/84102b9cf7624853a66205f87884b99c
Autor:
Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Talal El Zarif, Matthew P. Davidsohn, Heather McClure, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Praful Ravi, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and
Externí odkaz:
https://doaj.org/article/fd32672558144154be2b5ca22e877ed5
Autor:
Anna Patrikidou, Loic Chaigneau, Nicolas Isambert, Kyriaki Kitikidou, Ryan Shanley, Isabelle Ray-Coquard, Thibaud Valentin, Bettina Malivoir, Maryline Laigre, Jacques-Olivier Bay, Laurence Moureau-Zabotto, Emmanuelle Bompas, Sophie Piperno-Neumann, Nicolas Penel, Thierry Alcindor, Cécile Guillemet, Florence Duffaud, Anne Hügli, Cécile Le Pechoux, Frédéric Dhermain, Jean-Yves Blay, Paul W. Sperduto, Axel Le Cesne
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for s
Externí odkaz:
https://doaj.org/article/dc368f83526248ae8af12de0eb924877
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Biochemical recurrence is an evolving space in prostate cancer, with increasing multidisciplinary involvement. Androgen deprivation therapy has shown proof of its value in complementing salvage radiotherapy in high-risk biochemical relapsing patients
Externí odkaz:
https://doaj.org/article/232ce1f3c1b84fd491dc2e9987a84aff
Autor:
Ben Tran, Jose M. Ruiz‐Morales, Enrique Gonzalez‐Billalabeitia, Anna Patrikidou, Eitan Amir, Christoph Seidel, Carsten Bokemeyer, Christian Fankhauser, Thomas Hermanns, Alexey Rumyantsev, Alexey Tryakin, Margarida Brito, Aude Fléchon, Edmond Michael Kwan, Tina Cheng, Daniel Castellano, Xavier Garcia del Muro, Anis A. Hamid, Margaret Ottaviano, Giovannella Palmieri, Robert Kitson, Alison Reid, Daniel Y. C. Heng, Philippe L. Bedard
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 116-124 (2020)
Abstract Background Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life‐threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population.
Externí odkaz:
https://doaj.org/article/2123242758fc44e884e8dd8dcda39929
Autor:
Anna Patrikidou, Pierre Maroun, Jean-Jacques Patard, Hervé Baumert, Laurence Albiges, Christophe Massard, Yohann Loriot, Bernard Escudier, Mario Di Palma, Julia Arfi-Rouche, Laurence Rocher, Zahira Merabet, Alberto Bossi, Karim Fizazi, Pierre Blanchard
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 12, Iss , Pp 28-33 (2018)
Objectives: The initial treatment decision for newly diagnosed non-metastatic prostate cancer is complex. Multiple valid approaches exist, without a clear and absolute consensus for every clinical scenario, and therefore specialist opinions may vary.
Externí odkaz:
https://doaj.org/article/b8f9d1296ece43869e6462fcf174aa70
Autor:
Sabeeh‑ur‑Rehman Butt, Muhammad S Khan, Carmen Murias, Maria Reyes Gonzalez-Exposito, Hendrik-Tobias Arkenau, Anna Patrikidou
Publikováno v:
Annals of Urologic Oncology (2019)
As research focus in oncology has recently shifted to immunomodulation, the era of introduction of immunotherapeutic agents in the management of prostate cancer has just begun. With the success of checkpoint blockade drugs in certain advanced tumours
Externí odkaz:
https://doaj.org/article/e7565f81b586410fb1aa79859f130df3
Autor:
Anna Patrikidou, Walter Cazzaniga, Daniel Berney, Joost Boormans, Isabel de Angst, Domenico Di Nardo, Christian Fankhauser, Stefanie Fischer, Carmen Gravina, Hendrik Gremmels, Axel Heidenreich, Florian Janisch, Ricardo Leão, Nicola Nicolai, Christoph Oing, Jan Oldenburg, Robert Shepherd, Torgrim Tandstad, David Nicol
Publikováno v:
European Urology.
Context: Each year the European Association of Urology (EAU) produce a document based on the most recent evidence on the diagnosis, therapy, and follow-up of testicular cancer (TC). Objective: To represent a summarised version of the EAU guidelines o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be02f5c09508d6be09938b7cf7ef3c1a
https://doi.org/10.1016/j.eururo.2023.04.010
https://doi.org/10.1016/j.eururo.2023.04.010
Autor:
Ronan, Flippot, Anna, Patrikidou, Mihaela, Aldea, Emeline, Colomba, Pernelle, Lavaud, Laurence, Albigès, Natacha, Naoun, Pierre, Blanchard, Mario, Terlizzi, Camilo, Garcia, Alice, Bernard-Tessier, Alina, Fuerea, Mario, Di Palma, Bernard, Escudier, Yohann, Loriot, Giulia, Baciarello, Karim, Fizazi
Publikováno v:
Drugs. 82:719-733
Up to 25% of patients with metastatic prostate cancer present with germline or somatic DNA damage repair alterations, some of which are associated with aggressive disease and poor outcomes. New data have brought poly(ADP-ribose) polymerase (PARP) inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1398e43dcfe6b26bc901b4e5ad2776dc
https://doi.org/10.1007/s40265-022-01703-5
https://doi.org/10.1007/s40265-022-01703-5